Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)
Close on Nov 18, 2026Market cap $528.94MP/E –Yield –
Myriad Genetics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Myriad Genetics's pe ratio was 561.2× on Oct 31, 2019, against 24.3× a year earlier. Over the last 5 years it ranged from 12.3× to 561.2×, with a median of 25.6×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2019 | Oct 31, 2019 | 561.2× | +522.4 |
| 2018 | Dec 31, 2018 | 38.8× | +14.7 |
| 2017 | Dec 29, 2017 | 24.0× | +9.8 |
| 2016 | Dec 30, 2016 | 14.2× | −19.5 |
| 2015 | Dec 31, 2015 | 33.7× | +14.6 |
| 2014 | Dec 31, 2014 | 19.1× | +9.1 |
| 2013 | Dec 31, 2013 | 10.0× | −9.9 |
| 2012 | Dec 31, 2012 | 19.9× | +1.7 |
| 2011 | Dec 30, 2011 | 18.2× | +2.7 |
| 2010 | Dec 31, 2010 | 15.5× | −14.8 |
| 2009 | Dec 31, 2009 | 30.3× | – |
See a number that looks wrong?